The use of LNG-IUS-19.5mg in daily gynecological routine practice in Germany: data from the KyleenaTM Satisfaction Study (KYSS)

Author:

Römer Thomas1,Frenz Ann-Kathrin,Dietrich-Ott Susanne,Fiedler Anja

Affiliation:

1. University of Cologne: Universitat zu Koln

Abstract

Abstract Purpose: The Kyleena™ Satisfaction Study (KYSS) provided the first data on 19.5mg levonorgestrel-releasing intrauterine system (LNG-IUS-19.5mg) use in routine clinical practice. Here we report results from the German participants in KYSS. Methods: This prospective, observational, single-arm cohort study recruited women who independently chose to use LNG-IUS-19.5mg during routine counseling in Germany. Overall satisfaction and bleeding profile satisfaction, continuation rates, and safety profile were evaluated at 12 months or premature end of observation (EoO). Results: In the German study population, LNG-IUS-19.5mg placement was attempted in 508 women and successful in 506 women. Mean age was 32.3 years, and 60.0% (n=305/508) were parous. Placement was considered easy and associated with no more than mild pain, even in younger and nulliparous participants. Of those with satisfaction data available, 87.6% (n=388/443) were satisfied with LNG-IUS-19.5mg at 12 months/EoO. Satisfaction was similar for parous (86.9%, n=238/274) and nulliparous (88.8%, n=150/169) women, and was independent of age, prior contraceptive method, or reason for choosing LNG-IUS-19.5mg. Most participants (73.6%, n=299/406) were also satisfied with their bleeding profile at 12 months/EoO, independent of parity, age, prior contraceptive method, presence of amenorrhea or dysmenorrhea severity. The 12-month continuation rate was 84.1% (n=427/508). Most discontinuations were due to loss to follow-up (8.5%, n=43/508) or treatment-emergent adverse events (TEAEs) (4.7%, n=24/508). TEAEs were reported in 12.6% (n=64) of participants, with 9.3% (n=47) considered to have an LNG-IUS-19.5mg-related TEAE. Conclusion: Our real-world findings on LNG-IUS-19.5mg use in German KYSS participants reflected its suitability for a broad population, including young and nulliparous women. Clinical trial registration: NCT03182140 (date of registration: June 2017)

Publisher

Research Square Platform LLC

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3